Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief Scientific and Chief Medical Officer of Small Pharma (TSX.V: DMT, OTC: DMTTF). Dr. Carol Routhledge is an expert in psychedelic medicines, and she specializes in DMT.

In this interview, we attempted to answer the following questions:

What happens when you take DMT?

Can DMT help with depression?

Is DMT safe?

Small Pharma is a company that I am very excited about, as they are focussing on the psychedelic DMT, which I believe to have unlimited potential as a mental health drug.

Small Pharma is currently running a phase 2 Clinical Trial Attempting to treat Major Depressive Disorder using DMT, the world’s furthest progress DMT Study. We can expect results by the end of the year. If they are successful, the company will begin a phase 3 trial.

#DMT #SmallPharma #depression

Similar Posts

Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn

Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn

Listen, Videos

In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

Perhaps, psychedelics can treat mental health issues in general.

Perhaps, ketamine can be used to heal.

In the conversation, MDMA to treat addiction was also discussed.

Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

#Psychedelics #Awakn #PsychedelicStocks